

Amendments to the Claims

Claims 1-74 were previously canceled. Please cancel Claims 75-110. Claims 111-146 were previously presented but not entered. Please add new Claims 147-210. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-110. (Canceled)

111-146. (Not entered)

147. (New) An antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.
148. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
149. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the chemokine is MIP-1 α , MIP-1 β , RANTES, or a combination thereof.
150. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
151. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

152. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
153. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
154. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
155. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
156. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
157. (New) The antibody or antigen binding fragment thereof of Claim 147, wherein said antibody or antigen binding fragment thereof additionally inhibits HIV infection.
158. (New) An antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1 α , MIP-1 β , RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associated with binding of the chemokine to the receptor.

159. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
160. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
161. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
162. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
163. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
164. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
165. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

166. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
167. (New) The antibody or antigen binding fragment thereof of Claim 158, wherein said antibody or antigen binding fragment thereof additionally inhibits HIV infection.
168. (New) A composition comprising an antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.
169. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
170. (New) The composition of Claim 168, wherein the chemokine is selected from the group consisting of MIP-1 α , MIP-1 β and RANTES or a combination thereof.
171. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
172. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
173. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
174. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

175. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
176. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
177. (New) The composition of Claim 168, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
178. (New) The composition of Claim 168, wherein the antibody or antigen binding fragment additionally inhibits HIV infection.
179. (New) A composition comprising an antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1 α , MIP-1 β , RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor.
180. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
181. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
182. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

183. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
184. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
185. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
186. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
187. (New) The composition of Claim 179, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
188. (New) The composition of Claim 179, wherein the antibody or antigen binding fragment additionally inhibits HIV infection.
189. (New) A test kit for use in detecting the presence of a human chemokine receptor 5 (CCR5) in a biological sample comprising:
 - a) an antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor; and
 - b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.

190. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
191. (New) The test kit of Claim 189, wherein said chemokine is selected from the group consisting of MIP-1 α , MIP-1 β and RANTES or a combination thereof.
192. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
193. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
194. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
195. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
196. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
197. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
198. (New) The test kit of Claim 189, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.

199. (New) The test kit of Claim 189, wherein the antibody or antigen binding fragment additionally inhibits HIV infection.
200. (New) A test kit for use in detecting the presence of a human chemokine receptor 5 (CCR5) in a biological sample comprising:
 - a) an antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is MIP-1 α , MIP-1 β , RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment inhibits one or more functions associated with binding of the chemokine to the receptor; and
 - b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.
201. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment has specificity for human chemokine receptor 5 (CCR5).
202. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
203. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
204. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
205. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.

206. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment binds the second extracellular loop of human chemokine receptor 5 (CCR5).
207. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
208. (New) The test kit of Claim 200, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
209. (New) The test kit of Claim 200, wherein the antibody or antigen binding fragment additionally inhibits HIV infection.
210. (New) An antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is selected from the group consisting of MIP-1 α , MIP-1 β , and RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associate with binding of the chemokine to the receptor, and additionally inhibits HIV infection.